Insider Selling: Icon (NASDAQ:ICLR) Director Sells $569,625.00 in Stock

Icon Plc (NASDAQ:ICLR) Director Eugene Mccague sold 3,255 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $175.00, for a total value of $569,625.00. Following the transaction, the director directly owned 3,811 shares in the company, valued at $666,925. This trade represents a 46.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eugene Pacelli Mccague also recently made the following trade(s):

• On Tuesday, August 11th, Eugene Mccague sold 841 shares of Icon stock. The shares were sold at an average price of $164.29, for a total value of $138,167.89.

Icon Price Performance

Shares of ICLR stock opened at $169.68 on Friday. The firm has a market cap of $12.99 billion, a price-to-earnings ratio of 39.83, a PEG ratio of 8.03 and a beta of 1.20. Icon Plc has a 12 month low of $66.57 and a 12 month high of $203.91. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. The stock has a 50-day moving average price of $167.27 and a 200 day moving average price of $140.01.

Icon (NASDAQ:ICLR) last issued its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $3.26 EPS. Research analysts expect that Icon Plc will post 9.58 EPS for the current year.

Hedge Funds Weigh In On Icon

A number of large investors have recently made changes to their positions in ICLR. Abound Financial LLC acquired a new stake in Icon in the 4th quarter worth about $54,000. GAMMA Investing LLC boosted its stake in shares of Icon by 21.4% in the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after buying an additional 69 shares during the period. Blue Trust Inc. boosted its stake in shares of Icon by 207.5% in the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock valued at $73,000 after buying an additional 444 shares during the period. Global Retirement Partners LLC grew its position in Icon by 308.2% during the fourth quarter. Global Retirement Partners LLC now owns 547 shares of the medical research company’s stock worth $100,000 after buying an additional 413 shares in the last quarter. Finally, Fifth Third Bancorp grew its position in Icon by 1,062.0% during the first quarter. Fifth Third Bancorp now owns 918 shares of the medical research company’s stock worth $102,000 after buying an additional 839 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Robert W. Baird set a $194.00 target price on Icon in a report on Friday, July 31st. Jefferies Financial Group reiterated a “buy” rating and issued a $165.00 price objective on shares of Icon in a report on Friday, May 29th. Barclays raised their target price on shares of Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research report on Thursday, June 25th. UBS Group set a $160.00 price target on Icon in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. upped their price objective on Icon from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $170.40.

About Icon

ICON plc is a contract research and development organization that provides services to pharmaceutical, biotechnology, medical device and government clients. The company helps sponsors plan, manage and execute clinical development programs, supporting the progression of new medicines and healthcare products from early research through regulatory approval and commercialization.

Its services include clinical trial design and management, clinical data management, biostatistics, pharmacovigilance, regulatory consulting, medical affairs, laboratory services and real-world evidence.